Burton LeBlanc of Baron and Budd Appointed to Plaintiffs’ Steering Committee in GranuFlo, NaturaLyte Litigation

  Burton LeBlanc of Baron and Budd Appointed to Plaintiffs’ Steering Committee
  in GranuFlo, NaturaLyte Litigation

Business Wire

LOS ANGELES -- August 15, 2013

Burton LeBlanc, shareholder at Baron and Budd, has been appointed to the
Plaintiffs’ Steering Committee (PSC) in the litigation surrounding GranuFlo
and its sister product NaturaLyte. This committee oversees all activity in the
lawsuit and works to protect the rights of people who have filed lawsuits
against Fresenius for health issues allegedly linked to GranuFlo use.

Burton LeBlanc (Photo: Business Wire)

Burton LeBlanc (Photo: Business Wire)

“I’m honored to have been selected to such a prestigious team of upstanding
attorneys,” said LeBlanc. “I’m especially honored to have the opportunity to
help people who have been harmed by GranuFlo use, and I am confident that we
can achieve a positive outcome on their behalf.”

GranuFlo, along with NaturaLyte, was commonly used in dialysis treatments in
clinics owned and operated by Fresenius Medical Care, the manufacturer of
GranuFlo, although it was used in other dialysis facilities as well. GranuFlo
contains an ingredient that metabolizes in the body as bicarbonate, and
GranuFlo contains more of this ingredient than competitor pharmaceutical
products. Studies have found that elevated levels of bicarbonate in the blood
have the potential to cause heart attacks and other serious health issues.
Fresenius allegedly knew about these potentially dangerous side effects, as
evidenced by an internal company memo anonymously sent to the U.S. Food and
Drug Administration (FDA), yet failed to immediately alert the users of its

The PSC is appointed as part of the creation of a Multidistrict Litigation
(MDL). A MDL is created when a large number of lawsuits are filed against the
same entity regarding the same, or similar, issues. Once these cases are
consolidated into a MDL, the cases can move forward more quickly and

LeBlanc is a veteran trial attorney and currently serves as the president of
the American Association for Justice (AAJ). He has dedicated his career to
protecting the environment and ensuring access to the civil justice system.

Baron and Budd has been active in pharmaceutical litigation for decades. The
firm currently represents thousands of people who have allegedly been harmed
by use of the diabetes drug Avandia. Baron and Budd also represents numerous
states in litigation involving the marketing of Avandia. Previously the firm
was involved in negotiating a global settlement totaling $1.275 billion on
behalf of people who had been harmed by using diet drug Fen-Phen.

Baron and Budd is currently handling lawsuits related to GranuFlo,
Transvaginal Mesh, Lipitor and Actos. To learn more or see if you have a case,
call us at 1.866.855.4556 or

About Baron & Budd, P.C.

The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge,
Austin and Los Angeles, is a nationally recognized law firm with a 35-year
history of "Protecting What's Right" for people, communities and businesses
harmed by negligence. Baron & Budd's size and resources enable the firm to
take on large and complex cases. The firm represents individuals, governmental
and business entities in areas as diverse as water contamination, Gulf oil
spill, Qui Tam, California Proposition 65 violations, dangerous medications
and medical devices, Chinese drywall, insurance claims, consumer fraud,
securities fraud and asbestos-related illnesses such as mesothelioma.

Photos/Multimedia Gallery Available:



Baron & Budd
Susan Knape, 214-629-0596
Amanda Billo, 214-991-1051
Press spacebar to pause and continue. Press esc to stop.